Pharmaceutical Technology

MARCH 21, 2023

Pre-clinical-stage biotechnology firm InvisiShield Technologies has partnered with Gladstone Institutes to develop intranasal preventatives against airborne viral infections including influenza, respiratory syncytial virus (RSV) and SARS-CoV-2.

Patient Care 115

Patient Care Immunization Vaccines 115

Pharmaceutical Technology

JUNE 8, 2023

The European Commission (EC) has granted marketing authorisation for GSK’s respiratory syncytial virus (RSV) vaccine, Arexvy, for adults aged 60 years and above. The vaccine is indicated for active immunisation to prevent RSV-related lower respiratory tract disease (LRTD) in older adults.

Vaccines 59

Vaccines FDA 59

pharmaphorum

DECEMBER 15, 2022

However, this has led to increased transmission of other respiratory diseases and, as we’re already seeing, there are now some very real concerns about a lesser-known virus – respiratory syncytial virus, or RSV. RSV is one of the most common respiratory viruses, causing coughs and colds during the winter months.

Mayo Clinic 68

Mayo Clinic Hospitals Vaccines 68

Pharmaceutical Technology

APRIL 7, 2023

Enanta Pharmaceuticals has secured the US Food and Drug Administration’s (FDA) fast track designation for EDP-323 to treat respiratory syncytial virus (RSV). Consistent potency was also observed across a range of RSV clinical isolates in several cell types.

FDA 110

FDA Dosage 110

Pharmafile

APRIL 12, 2023

Biotechnology company Moderna has announced clinical updates detailing the expansion and advancement of its mRNA pipeline, which includes treatments for COVID-19, influenza and respiratory syncytial virus (RSV), amongst others.

Vaccines 52

Vaccines 52

Pharmafile

DECEMBER 23, 2022

The aim of the partnership is to generate a ready supply of UK-produced mRNA vaccines for COVID-19 and other infectious diseases like flu and respiratory syncytial virus (RSV). read more.

Vaccines 64

Vaccines 64

Pharmafile

JANUARY 5, 2023

The FDA has accepted an application for nirsevimab as the first protective option to combat respiratory syncytial virus (RSV) disease for all infants. If approved, the drug would become the first broadly protection option for RSV.

FDA 59

FDA Communication 59

STAT

APRIL 9, 2024

A Pfizer vaccine showed the potential to protect adults ages 18 to 59 who are at increased risk of getting severely sick from respiratory syncytial virus in a late stage clinical trial, CNBC tells us. Landlords in places like greater Boston suddenly found they had vacant labs for the first time in a decade.

Vaccines 79

Vaccines 79

PharmaShots

APRIL 10, 2023

Shots: The US FDA has granted FTD for Enanta’s EDP-323 (L-protein inhibitor) for the treatment of the respiratory syncytial virus. EDP-323 is being studied in a P-I study evaluating the safety, tolerability, and PK with expected results in Q2’23 The company plans to present new preclinical PK data at ECCMID 20323.

Vaccines 40

Vaccines FDA 40

The People's Pharmacy

JUNE 1, 2023

I’m talking about a really nasty upper respiratory tract infection. I speak with some authority because I am pretty sure I caught this virus around mid-March. But within a few days of returning home, almost everyone was sick with a really nasty upper respiratory tract infection. She was negative for COVID, several times.

Vaccines 71

Vaccines Immunization FDA 71

European Pharmaceutical Review

AUGUST 22, 2023

Abrysvo is approved for pregnant individuals to prevent lower respiratory tract disease (LRTD) and severe LRTD caused by respiratory syncytial virus (RSV) in infants. The US Food and Drug Administration (FDA)-approved treatment, is the first RSV vaccine indicated for infants from birth to six months of age.

Vaccines 88

Vaccines FDA 88

Hospital Pharmacy Europe

SEPTEMBER 23, 2022

Nirsevimab has been recommended by the EMA to prevent respiratory syncytial virus in new-born’s and infants during their first RVS season. Respiratory syncytial virus (RSV) is a common cause of childhood infections and which would normally lead to mild, cold-like symptoms. Nirsevimab clinical efficacy.

Hospitals 52

Hospitals 52

Pharmaceutical Technology

JANUARY 16, 2023

Recent cases in the pharmaceutical sector include Poolbeg Pharma finding more than one respiratory syncytial virus (RSV) vaccine candidate with AI by going through a vast amount of early stage clinical data to prioritise candidates and reposition them as novel treatments for RSV infection.

Pharmaceutical Companies 121

Pharmaceutical Companies Pharmaceutical Companies Vaccines 121

pharmaphorum

DECEMBER 22, 2022

It also said the alliance will see Moderna invest in R&D in the UK over the next 10 years, including running a number of clinical trials and providing grant funding to UK universities, while the manufacturing facility will create more than 150 highly skilled jobs. The first vaccines are due to be produced at the new facility in 2025.

Vaccines 121

Vaccines 121

Hospital Pharmacy Europe

OCTOBER 17, 2022

An RSV vaccine provided a high overall efficacy in older adults especially among patients with a severe lower respiratory tract infection. Respiratory syncytial virus (RSV) is one of the common viruses that cause coughs and colds and causes severe respiratory illnesses in infants and older adults who frequently require hospitalisation.

Vaccines 59

Vaccines Hospitals FDA 59

Hospital Pharmacy Europe

NOVEMBER 9, 2022

In a press release by the manufacturer Astra Zeneca , it is revealed that Nirsevimab (brand name Beyfortus) has been approved by the European Commission for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants during their first RSV season. p < 0.001).

Hospitals 52

Hospitals 52

pharmaphorum

JULY 12, 2022

Researchers in the US have started a clinical trial of a vaccine against Nipah virus, a serious infection caught from animals that has a fatality rate of between 40% and 70%, developed by mRNA specialist Moderna. “The need for a preventive Nipah virus vaccine is significant,” he added.

Vaccines 52

Vaccines Documentation Immunization 52

pharmaphorum

DECEMBER 1, 2021

The vaccine has just started clinical testing, but is designed to control the growth of C acnes on the skin and prevent it from damaging the cellular lining of pores, which can lead to scarring in severe acne cases. It will highlight vaccines for pneumococcal disease, meningitis, respiratory syncytial virus (RSV), influenza, and chlamydia.

Vaccines 105

Vaccines FDA 105

Pharmaceutical Technology

FEBRUARY 23, 2023

This collaboration is expected to help expedite the clinical manufacturing of RVM-V001 and future mRNA-based vaccines that target infectious diseases such as Clostriodioides difficile infection (CDI) and Respiratory syncytial virus (RSV).

Vaccines 115

Vaccines Communication 115

pharmaphorum

JULY 21, 2022

GSK’s former head of vaccines R&D – Dr Emmanuel Hanon – is heading up a new biotech called Vicebio that will go up against his former employer with a vaccine against respiratory syncytial virus (RSV) infections. ” He said. ” The post Ex-GSK vaccine chief to lead new UK biotech Vicebio appeared first on.

Vaccines 104

Vaccines Immunization 104

PharmaShots

JUNE 23, 2023

Gilead Receives EMA’s CHMP Positive Opinion of Trodelvy (sacituzumab govitecan) for Pre-Treated HR+/HER2- Metastatic Breast Cancer Date: June 23, 2023 | Tags: Gilead, Trodelvy, sacituzumab govitecan, HR+/HER2- Metastatic Breast Cancer, Regulatory, EMA, CHMP, Positive Opinion Sarepta Therapeutics’ Elevidys Receives the US FDA’s Accelerated (..)

FDA 40

FDA 40

pharmaphorum

JUNE 29, 2022

Already competing to bring the first vaccine against respiratory syncytial virus (RSV) to market, Pfizer and GSK are also fighting a patent infringement battle in the courts. com website.

Vaccines 102

Vaccines 102

Pharmaceutical Technology

NOVEMBER 21, 2022

This will aid in the production of new raw materials and possible clinical-grade assets to develop mRNA vaccines and therapies for infectious diseases, as well as other ailments with unmet needs. It commenced a first-in-human clinical trial of the vaccines in September this year. .

Vaccines 52

Vaccines 52

pharmaphorum

OCTOBER 12, 2022

“Continuing our strategic alliance with Merck is an important milestone as we continue to grow our mRNA platform with promising clinical programmes in multiple therapeutic areas.” The post Merck gets on board with Moderna cancer vaccine in $250m deal appeared first on.

Vaccines 105

Vaccines 105

pharmaphorum

OCTOBER 13, 2022

GSK’s vaccine against respiratory syncytial virus (RSV) is one of the top prospects in its pipeline, but also one with considerable competition, so needs strong data to support the programme. Top of the list is an overall protective efficacy against RSV lower respiratory tract disease of 82.6%

Vaccines 104

Vaccines 104

Pharmaceutical Technology

JUNE 6, 2023

According to Globaldata, it is involved in 5 clinical trials, which are ongoing. The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress. Pharma Mar also offers kits used for diagnosis of influenza A and B and respiratory syncytial virus.

Compounding 40

Compounding 40

pharmaphorum

NOVEMBER 30, 2021

Dormitzer also took the lead on Pfizer’s respiratory syncytial virus (RSV) vaccine candidates, which are in late-stage testing and a race to market with GSK own experimental shots, as well as a BioNTech-partnered influenza jab BNT161, which started clinical trials earlier this year.

Vaccines 98

Vaccines 98

pharmaphorum

JUNE 23, 2022

Enanta has a long heritage in the development of antiviral compounds, working with AbbVie on therapies for hepatitis C virus (HCV) infection including Viekira Pak (paritaprevir/ritonavir/ombitasvir/dasabuvir) and Mavyret/Maviret (glecaprevir/pibrentasvir).

Compounding 52

Compounding Documentation FDA 52

pharmaphorum

MAY 9, 2022

Johnson & Johnson has halved the size of its collaboration with Bavarian Nordic on vaccine development, jettisoning its stake in shots targeting human papillomavirus (HPV) and hepatitis B virus (HBV). ” The partners’ HPV candidate had advanced into phase 1/2 clinical trials.

Vaccines 52

Vaccines 52

pharmaphorum

JANUARY 18, 2023

Moderna is looking to make a swift dash to the finish line with its respiratory syncytial virus (RSV) vaccine candidate, based on the same mRNA technology as its COVID-19 shots, with a filing in with the FDA in the first half of this year. Look out, Pfizer and GSK. for placebo.

Vaccines 52

Vaccines Adverse Reactions FDA 52

pharmaphorum

MARCH 22, 2022

Bavarian Nordic has licensed rights to its respiratory syncytial virus (RSV) vaccine in China and certain other Asian markets to Shanghai’s Nuance Pharma in a $225 million deal. million tied to clinical, regulatory, and commercial milestones as well as royalties on sales if MVA-BN RSV is launched in those markets.

Vaccines 52

Vaccines FDA 52

pharmaphorum

JUNE 11, 2021

“Based on the robust clinical evidence we have to-date, sutimlimab significantly inhibits haemolysis and has the potential to be an important new treatment for CAD,” said Karin Knobe, head of development, rare, and rare blood disorders at Sanofi.

FDA 95

FDA Immunization Labelling 95

pharmaphorum

JUNE 23, 2021

GlaxoSmithKline’s pitch to shareholders kicked off this afternoon with an optimistic view of its late-stage pipeline – including some big sales predictions for products like its respiratory syncytial virus (RSV) vaccine and new blood cancer drug Blenrep. billion takeover of Tesaro in 2019. £1

Vaccines 100

Vaccines 100

PharmaShots

APRIL 14, 2023

Ocugen Reports Preliminary Results from the P-I/II Trial of OCU400 for the Treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis Date: Apr 14, 2023 | Tags: Ocugen, OCU400, Retinitis Pigmentosa, Leber Congenital Amaurosis, Clinical Trial, P-I/II Trial Candesant Biomedical Receives the US FDA Clearance of Brella SweatControl Patch for Primary (..)

FDA 40

FDA 40

Digital Pharmacist

AUGUST 31, 2023

Whether addressing acute pharyngitis, influenza, COVID-19, or other respiratory infections, the ability to swiftly identify causative agents empowers healthcare providers to make informed decisions that significantly impact patient outcomes. Navigating State Regulations for POCT State regulations influence rapid diagnostic testing protocols.

Independent Pharmacies 52

Independent Pharmacies Scheduling Appointments Hospitals Communication 52

pharmaphorum

JUNE 29, 2021

Sanofi has just significantly increased its investment in mRNA vaccine development, earmarking €400 million ($475 million) a year in R&D funding to an effort that it hopes will deliver at least six clinical-stage candidates by 2025. .

Vaccines 52

Vaccines 52

pharmaphorum

JANUARY 21, 2021

Capsule’s software is already used by more than 2,800 healthcare organisations around the world for device integration, vital signs monitoring and clinical surveillance services, including in intensive care units. That agreement comes a few weeks after Philips signed a $2.8 to develop a digital approach to personalised fertility treatment.

Medical Records 52

Medical Records Patient Care Hospitals FDA 52